MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

TrovaGene Company Profile (NASDAQ:TROV)

Consensus Ratings for TrovaGene (NASDAQ:TROV) (?)
Ratings Breakdown: 6 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $7.20 (58.24% upside)

Analysts' Ratings History for TrovaGene (NASDAQ:TROV)
Show:
DateFirmActionRatingPrice TargetActions
6/6/2016Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Piper JaffrayReiterated RatingHold$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Leerink SwannReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/11/2016Cantor FitzgeraldReiterated RatingHold$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2016ArgusDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Avondale PartnersReiterated RatingMarket Perform$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for TrovaGene (NASDAQ:TROV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.29)($0.36)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.25)($0.26)$100.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.24)($0.41)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015($0.23)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.26)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q3 14($0.25)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.24)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.23)($0.17)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.19)($0.05)$0.15 million$0.05 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q313($0.22)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q213($0.15)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2013Q113($0.09)($0.07)$0.03 million$0.12 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for TrovaGene (NASDAQ:TROV)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20162($0.33)($0.33)($0.33)
Q3 20162($0.38)($0.37)($0.38)
Q4 20161($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)
Dividend History for TrovaGene (NASDAQ:TROV)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for TrovaGene (NASDAQ:TROV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
8/12/2015Antonius SchuhCEOBuy20,000$5.45$109,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Stanley TennantDirectorBuy10,000$6.06$60,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Steve ZaniboniCFOBuy15,000$5.43$81,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Bridger Management, LlcMajor ShareholderBuy140,000$8.75$1,225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015Bridger Management, LlcMajor ShareholderBuy300,000$6.90$2,070,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Bridger Management, LlcMajor ShareholderBuy263,286$5.36$1,411,212.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/6/2015Bridger Management, LlcMajor ShareholderBuy444,444$4.50$1,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2014Steve ZaniboniCFOBuy6,329$3.95$24,999.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Thomas Phd AdamsDirectorSell19,200$8.19$157,248.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2012Stanley TennantDirectorBuy25,000$4.82$120,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2012Gabriel CerroneDirectorBuy7,800$2.35$18,330.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2012Gabriel CerroneDirectorBuy15,000$2.24$33,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for TrovaGene (NASDAQ:TROV)
DateHeadline
06/27/16 07:46 AMStrong Sell Calls Recommendations For TrovaGene, Inc. (NASDAQ:TROV) At 0 - Investor Newswire
06/27/16 07:46 AMTrovaGene, Inc. (TROV) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 06:55 PMTrovaGene, Inc. (NASDAQ:TROV) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 04:48 PMETF’s with exposure to TrovaGene, Inc. : June 24, 2016 -
06/23/16 09:28 AMTrovaGene, Inc. (NasdaqCM:TROV) Stock Momentum Hits Weakness - CML News
06/20/16 06:26 PMStrong Buy Calls Count For TrovaGene, Inc. (NASDAQ:TROV) At 1 - Investor Newswire
06/20/16 06:26 PMThis Weeks Broker Views For TrovaGene, Inc. (TROV) - Fiscal Standard
06/17/16 06:40 PMCell-Free DNA (cfDNA) Testing Global Market - Forecast to 2022
06/17/16 09:35 AMTrovaGene, Inc. (TROV) Current Analyst Ratings - Fiscal Standard
06/15/16 06:47 PMHC Stocks Reports Analysis: TrovaGene Inc (NASDAQ:TROV), Prima BioMed Ltd (ADR) (NASDAQ:PBMD) - share market updates (press release)
06/13/16 06:24 PMStock's Move to Focus: DENTSPLY International Inc. (NASDAQ:XRAY) , TrovaGene, Inc. (NASDAQ:TROV) - Street Updates
06/12/16 06:57 PMTrend Of Rating Given To TrovaGene, Inc. (NASDAQ:TROV) - Investor Newswire
06/10/16 07:12 PMGlobal Cell-Free DNA (cfDNA) Testing Market 2016 Analysis and Forecast to 2022
06/10/16 07:12 PMGlobal Cell-Free DNA (cfDNA) Testing Market 2016 Share, Trend, Segmentation and Forecast to 2022
06/08/16 07:28 PMASCO Oral Presentation Demonstrates Trovagene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in ... - PR Newswire (press release)
06/07/16 09:47 AMGlobal Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2016-2019 - Research and Markets
06/07/16 09:47 AMCancer Diagnostics Market to register a healthy CAGR for the forecast period, 2015-2025
06/07/16 08:39 AMTrovaGene: Trovera Liquid Biopsy Urine Test Results Positive -
06/06/16 10:18 AMASCO Oral Presentation Demonstrates Trovagene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer - [at noodls] - SAN DIEGO, June 6, 2016/PRNewswire / -- Trovagene, Inc. (NASDAQ: TROV), a developer of circulating tumor DNA (ctDNA) molecular diagnostics, announced the presentation of clinical results demonstrating ...
06/03/16 02:45 PMETF’s with exposure to TrovaGene, Inc. : June 3, 2016 -
06/02/16 07:26 PMBuy, Sell Or Hold Rating For TrovaGene, Inc. (TROV)? - Share Trading News - Buy, Sell Or Hold Rating For TrovaGene, Inc. (TROV)?Share Trading News05/11/2016 – TrovaGene, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 5 price target on the stock. 04/27/2016 – TrovaGene, Inc. was downgraded to “hold” by analysts at Argus. 04/26/2016 – TrovaGene, Inc. had ...
06/02/16 10:08 AMStrong Sell Calls Count For TrovaGene, Inc. (NASDAQ:TROV) At 0 - Investor Newswire - Strong Sell Calls Count For TrovaGene, Inc. (NASDAQ:TROV) At 0Investor NewswireThe Sell calls on TrovaGene, Inc. (NASDAQ:TROV) were 0. Two months earlier 1 were the Strong Buy calls whereas Strong Sell calls were 0. During this period, the hold calls were 3. The buy recommendations were 0 and sell calls count was 0. Analyst score ...and more »
06/02/16 10:08 AMTrovaGene Inc Stock Price Declines Today - HNN - TrovaGene Inc Stock Price Declines TodayHNNThe stock of TrovaGene Inc (NASDAQ:TROV) is a huge mover today! The stock decreased 3.23% or $0.17 on June 1, hitting $5.1. About 377,425 shares traded hands. TrovaGene Inc (NASDAQ:TROV) has risen 6.25% since October 26, 2015 and is ...and more »
05/31/16 09:56 AMIPO Underwriters of the Week: May 23 – 27 / plus Reg A+ Form Worksheet - Registrant Form Underwriter 1 Underwriter 2 Underwriter 3 + BLACKSTONE ALTERNATIVE ALPHA FUND N-2 Blackstone Advisory Partners L.P. ~ ~ BLACKSTONE ALTERNATIVE ALPHA FUND II N-2 Blackstone Advisory Partners L.P. ~ ~ TROVAGENE ... TWILIO INC S-1 Goldman ...
05/23/16 06:40 PMTrovaGene, Inc. (NASDAQ:TROV) Quarterly EPS From Continuing Operations Stands At $-0.3449 - Investor Newswire - TrovaGene, Inc. (NASDAQ:TROV) Quarterly EPS From Continuing Operations Stands At $-0.3449Investor NewswireTrovaGene, Inc. (NASDAQ:TROV) diluted EPS from parent firm came at $-1.0385 for the year ended 2016-03-31. For the quarter ended 2016-03-31 it came at $-1.0385. TrovaGene, Inc. (NASDAQ:TROV) posted net basic EPS of $-0.76 for the year ended ...and more »
05/23/16 11:51 AMNext Weeks Broker Price Targets For TrovaGene, Inc. (TROV) - Share Trading News - Next Weeks Broker Price Targets For TrovaGene, Inc. (TROV)Share Trading News05/11/2016 – TrovaGene, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 5 price target on the stock. 04/27/2016 – TrovaGene, Inc. was downgraded to “hold” by analysts at Argus. 04/26/2016 – TrovaGene, Inc. had ...
05/23/16 11:51 AMAnalysts Set 1-Year Price Target Of $6.375 On TrovaGene, Inc. (NASDAQ:TROV) Stock - Investor Newswire - Analysts Set 1-Year Price Target Of $6.375 On TrovaGene, Inc. (NASDAQ:TROV) StockInvestor NewswireSell-side analysts reveal their outlook on TrovaGene, Inc. (NASDAQ:TROV) stock. As of 2016-05-22, the stock has ABR of 2.5. This methodology prompts shareholders to invest in stock if it has a rating of 1. The ABR was known considering the price ...and more »
05/23/16 11:51 AMHC Sector Stocks Review: TrovaGene Inc (NASDAQ:TROV), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release) - HC Sector Stocks Review: TrovaGene Inc (NASDAQ:TROV), Allergan plc Ordinary Shares (NYSE:AGN)share market updates (press release)Shares of TrovaGene Inc (NASDAQ:TROV) ended Friday session in red amid volatile trading. The shares closed down -0.06 points or -1.20% at $4.93 with 530,936.00 shares getting traded. Post opening the session at $5.21, the shares hit an intraday low of ...and more »
05/22/16 11:23 AMWhat's Propelling TrovaGene Inc to Decline So Much? - Wall Street Hints and News - What's Propelling TrovaGene Inc to Decline So Much?Wall Street Hints and NewsThe stock of TrovaGene Inc (NASDAQ:TROV) is a huge mover today! The stock decreased 1.20% or $0.06 on May 20, hitting $4.93. About 530,936 shares traded hands. TrovaGene Inc (NASDAQ:TROV) has declined 10.69% since October 15, 2015 and is ...Is it Time to Cash in Profits on TrovaGene, Inc. (NASDAQ:TROV)Franklin IndependentTrovaGene, Inc. (TROV) Updated Broker Price TargetsShare Trading NewsTrovagene New (NASDAQ:TROV) Short Interest Decreased By 4.86%The PostBenchmark Monitorall 7 news articles »
05/20/16 11:12 AMETF’s with exposure to TrovaGene, Inc. : May 20, 2016 -
05/20/16 10:31 AMTargeted Movers: TrovaGene, Inc. (NASDAQ:TROV) , Aratana Therapeutics, Inc. (NASDAQ:PETX) - Street Updates - Targeted Movers: TrovaGene, Inc. (NASDAQ:TROV) , Aratana Therapeutics, Inc. (NASDAQ:PETX)Street UpdatesTrovaGene, Inc. (NASDAQ:TROV) accumulated +2.89%, closing at $4.99 after floating between $4.77 and $5.40. The company has market capitalization of $149.01M. It has twelve month low of $2.85 and twelve month high of $13.58. The recent traded ...and more »
05/19/16 01:50 PMTrovaGene, Inc. :TROV-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/19/16 12:04 PMTROVAGENE, INC. Financials -
05/19/16 10:11 AMTrovaGene Inc.: Large Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform ... - The Wall Street Transcript - TrovaGene Inc.: Large Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform ...The Wall Street TranscriptSAN DIEGO, May 19, 2016/PRNewswire / -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that diagnostic performance results using the Company's Precision Cancer Monitoring® platform to detect and ...and more »
05/19/16 07:32 AMLarge Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting - [at noodls] - SAN DIEGO, May 19, 2016/PRNewswire / -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that diagnostic performance results using the Company's Precision ...
05/19/16 07:08 AM8:08 am TrovaGene announces presentation of results using its Precision Cancer Monitoring platform to detect and monitor EGFR T790M in the urine of non-small cell lung cancer patients at the 2016 ASCO on June 6 -
05/18/16 03:32 PMTROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
05/18/16 11:00 AMBroker Outlook For TrovaGene, Inc. (TROV) - Share Trading News - Broker Outlook For TrovaGene, Inc. (TROV)Share Trading NewsTrovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines.
05/18/16 11:00 AMTrovaGene, Inc. (NASDAQ:TROV) Hovering Around $4.52 - Investor Newswire - TrovaGene, Inc. (NASDAQ:TROV) Hovering Around $4.52Investor NewswireOn performing technical analysis of TrovaGene, Inc. (NASDAQ:TROV) stock, it is noted that the stock is $-0.10 points away -2.15% from its fifty-day MA of $4.73. It is $-0.36 or -7.22% away $4.99, the 200-day MA (Moving Average) of stock. Also, the ...and more »
05/18/16 11:00 AMHC Stocks Alerts: Lpath (NASDAQ:LPTN), TrovaGene (NASDAQ:TROV), Prima BioMed (NASDAQ:PBMD) - share market updates (press release) - share market updates (press release)HC Stocks Alerts: Lpath (NASDAQ:LPTN), TrovaGene (NASDAQ:TROV), Prima BioMed (NASDAQ:PBMD)share market updates (press release)Shares of Lpath, Inc. (NASDAQ:LPTN) ended Tuesday session in green amid volatile trading. The shares closed up +0.014 points or 8.71% at $0.180 with 369,735.00 shares getting traded. Post opening the session at $0.16, the shares hit an intraday low of ...
05/17/16 06:27 PMBuy Calls Count For TrovaGene, Inc. (NASDAQ:TROV) At 0 - RealistInvestor.com - Buy Calls Count For TrovaGene, Inc. (NASDAQ:TROV) At 0RealistInvestor.comZacks line of rating gives scores to firms on a basic 1-5 scale. As per this rating line, a score close to the lower band of 1-2 indicates a Buy, 3 rating calls for Hold while 4 or 5 rating denotes Sell. Most of the research firms have their self ...and more »
05/17/16 03:33 PMTROVAGENE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/16/16 11:31 PMTrovaGene, Inc. (NASDAQ:TROV) Reports Basic Consolidated EPS At $-1.0484 - Investor Newswire - TrovaGene, Inc. (NASDAQ:TROV) Reports Basic Consolidated EPS At $-1.0484Investor NewswireFrom the parent firm, TrovaGene, Inc. (NASDAQ:TROV) diluted EPS came at $-1.0385 for the year ended 2015-12-31. For the quarter ended 2015-12-31 it came at $-1.0385. TrovaGene, Inc. (NASDAQ:TROV) posted net basic EPS of $-0.76 for the year ended ...
05/16/16 12:00 PMTop Wall Street Stories: TrovaGene, Inc. (NASDAQ:TROV), Kornit Digital Ltd. (NASDAQ:KRNT), Extreme Networks Inc ... - KC Register - Top Wall Street Stories: TrovaGene, Inc. (NASDAQ:TROV), Kornit Digital Ltd. (NASDAQ:KRNT), Extreme Networks Inc ...KC RegisterOn 11 May, TrovaGene, Inc. (NASDAQ:TROV) reported after the close of the market on Tuesday that its first quarter revenues fell nearly 6 percent year over year as its net loss increased 43 percent. On Friday TrovaGene, Inc. (NASDAQ:TROV) share price ...
05/16/16 12:00 PMTrovaGene, Inc. (NASDAQ:TROV) One-Year Price Projection At $6.1 - Investor Newswire - TrovaGene, Inc. (NASDAQ:TROV) One-Year Price Projection At $6.1Investor NewswireSell-side analysts are certain on the prospect of TrovaGene, Inc. (NASDAQ:TROV) stock. As of 2016-05-15, the stock ABR stands at 2.6. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such stocks ...and more »
05/16/16 12:00 PMStocks within Traders Screening: KemPharm, Inc. (NASDAQ:KMPH) , TrovaGene, Inc. (NASDAQ:TROV) - Street Updates - Stocks within Traders Screening: KemPharm, Inc. (NASDAQ:KMPH) , TrovaGene, Inc. (NASDAQ:TROV)Street UpdatesOn 5/13/2016, shares of KemPharm, Inc. (NASDAQ:KMPH) fell -8.93% in trading session and finally closed at $6.02. The company most recent volume stood at 629.02 thousand shares as compared to its average volume of 173.16 thousand shares. Over the ...
05/14/16 06:13 PMTrovagene (TROV) Announces Presentation of PCM Platform Data at 2016 AACR - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Trovagene, Inc. (Nasdaq: TROV) announced that clinical study results featuring the Company's Precision Cancer Monitoring (PCM) platform were presented at the 2016 AACR ...
05/14/16 12:06 AMAnalysts Offer Insights on Healthcare Companies: Theravance Biopharma (NASDAQ: TBPH), TrovaGene Inc (NASDAQ ... - Analyst Ratings - Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (NASDAQ: TBPH), TrovaGene Inc (NASDAQ ...Analyst RatingsCompanies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Theravance Biopharma (NASDAQ: TBPH), TrovaGene Inc (NASDAQ: TROV), Immune Design Corp (NASDAQ: IMDZ) and Ignyta Inc (NASDAQ: RXDX).
05/14/16 12:06 AMTrovaGene Inc (TROV) Reports Mixed Quarterly Earnings - Bidness ETC - Bidness ETCTrovaGene Inc (TROV) Reports Mixed Quarterly EarningsBidness ETCTrovaGene Inc (NASDAQ:TROV) shares surged as much as 8.41% after the company announced its first quarter of fiscal year 2016 (1QFY16) earnings results. The stock is trading up more than 6% during the early hours of trading. The company recorded a ...TrovaGene, Inc. (TROV) Updated Broker RatingsRisers & FallersTrovaGene Inc (NASDAQ:TROV)'s Company Shares Decreased 40.21% After Low VolatilityThe PostTrovagene (TROV) Announces Presentation of PCM Platform Data at 2016 AACRStreetInsider.comall 4 news articles »
05/13/16 06:56 PMTrovaGene Inc (TROV) Reports Mixed Quarterly Earnings - TrovaGene Inc (NASDAQ:TROV) shares surged as much as 8.41% after the company announced its first quarter of fiscal year 2016 (1QFY16) earnings results. The stock is trading up more than 6% during the early hours of trading. The company recorded a loss of $ ...
About TrovaGene

TrovaGene logoTrovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TROV
  • CUSIP:
Key Metrics:
  • Previous Close: $4.80
  • 50 Day Moving Average: $4.65
  • 200 Day Moving Average: $4.85
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $135.87M
  • Current Quarter EPS Consensus Estimate: $-1.30 EPS
Additional Links:
TrovaGene (NASDAQ:TROV) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha